Get the Stockscreener App
24.51
7.36%
1.68
After Hours:
26.48
1.97
+8.04%
Oruka Therapeutics Inc stock is traded at $24.51, with a volume of 162.45K.
It is up +7.36% in the last 24 hours and up +0.00% over the past month.
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$22.83
Open:
$23.97
24h Volume:
162.45K
Relative Volume:
8.86
Market Cap:
$799.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.28%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.28
$25.90
1-Week Range:
$22.51
$25.98
52-Week Range:
$22.51
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
(720) 940-2200
Address
10170 CHURCH RANCH WAY, WESTMINSTER
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan
Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks
Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World
Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World
Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online
Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily
‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer
Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Leerink Partners starts drug developer Oruka with 'outperform' - XM
Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga
Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter
Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World
Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT
Oruka to advance psoriasis programs into clinic next year - BioWorld Online
Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK
Biotech firm enters $200M agreement - The Business Journals
Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada
Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com
Oruka Therapeutics secures $200 million in PIPE financing - Investing.com
Oruka Therapeutics secures $200 million in PIPE financing - Investing.com UK
Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire
Oruka Therapeutics Announces $200 Million Private Placement - StockTitan
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World
Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera
Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World
Oruka announces closing of merger with ARCA Biopharma - TipRanks
ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):